Area of technology: Pharma

Sub-category: Formulation

IP Status: Granted in India and Filed PCT

Brief description: A formulation, which is a combination therapy for the treatment of type 2 diabetes in patients. The bitter taste of the aqueous formulation is masked by a formulation comprising 3 to 37 % w/v Poloxamer or poloxamine, 0.1 to 2 % w/v HPMC, 0.1 to 3% w/v liposomes and optionally maltodextrin. The formulation is safe, cost-effective, and results in sustained drug release for 24 hours. It is suitable for oral administration in patients with type 2 diabetes.

Key advantages

The formulation is safe, cost-effective, and results in sustained drug release for 24 hours

Stage: Lab stage

Expectations: Open for licensing, assignment and joint venture

Get in Touch now!